Trial reportObesity (Silver Spring, Md.)2019
A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss.
Trial report in Obesity (Silver Spring, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it.
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Guideline
- Trial
- A Randomized, Double-Blind, Placebo-Controlled Pilot Trial With Open-Label Extension of Sirona, a Hydrogel for Weight Loss.Obesity (Silver Spring, Md.) · 2026Trial
- Efficacy and safety of a novel oral hydrogel capsule in adults with overweight or obesity: the pivotal randomized RESET study.Obesity (Silver Spring, Md.) · 2025Trial
- Anti-Obesity Effects of a Collagen with Low Digestibility and High Swelling Capacity: A Human Randomized Control Trial.Nutrients · 2024Trial
- Non-Systemic Oral Cellulose-Based Superabsorbent Hydrogels for Weight Management: Potential Drug-Device Interactions Estimated by a Simplified In Vitro Assay.Pharmaceutics · 2026Article
- Innovative Hydrogels: A Novel Approach to Tackle Obesity and Its Associated Health Risks.ACS materials Au · 2026Review
- Nanomaterial-driven modulation of lipid metabolism: Novel strategies toward precision obesity treatment.Bioactive materials · 2026Review
- Palmitoylethanolamide in Human and Animal Obesity.Molecules (Basel, Switzerland) · 2026Review
- Bioresorbable RFID capsule for assessing medication adherence.Nature communications · 2026Article
- A GI-Interoceptive Threat Theory of Restrictive Eating: Insights From Active Inference and Chronic Pain.Brain and behavior · 2025Review
- Establishing the relationships between obesity and genetically predicted serum micronutrient levels: a multivariable Mendelian randomization analysis.Eating and weight disorders : EWD · 2025Article
- Role of pancreatic lipase inhibition in obesity treatment: mechanisms and challenges towards current insights and future directions.International journal of obesity (2005) · 2025Review
- Endobariatric systems: Strategic integration of endoscopic therapies in the management of obesity.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Review
- A Guideline-Directed Approach to Obesity Treatment.Diabetes spectrum : a publication of the American Diabetes Association · 2024Article
- 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2024.Diabetes care · 2024Review
- A vibrating ingestible bioelectronic stimulator modulates gastric stretch receptors for illusory satiety.Science advances · 2023Article
- Effects of an oral biodegradable device used for 12 weeks on weight reduction, cardiovascular risk factors, satiety, snacking, and meal size.Obesity pillars · 2023Article
- Obesity Management in Adults: A Review.JAMA · 2023 · on this mapReview
- Biomimetic superabsorbent hydrogel acts as a gut protective dynamic exoskeleton improving metabolic parameters and expanding A. muciniphila.Cell reports. Medicine · 2023Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
- Erratum issued
Authors and funding
24 authors.
Funding
Abstract
objectiveThis study aims to assess the efficacy and safety of Gelesis100, a novel, nonsystemic, superabsorbent hydrogel to treat overweight or obesity.
methodsThe Gelesis Loss Of Weight (GLOW) study was a 24-week, multicenter, randomized, double-blind, placebo-controlled study in patients with BMI ≥ 27 and ≤ 40 kg/m
resultsGelesis100 treatment caused greater weight loss over placebo (6.4% vs. 4.4%, P = 0.0007), achieving 2.1% superiority but not 3% super-superiority. Importantly, 59% of Gelesis100-treated patients achieved weight loss of ≥ 5%, and 27% achieved ≥ 10% versus 42% and 15% in the placebo group, respectively. Gelesis100-treated patients had twice the odds of achieving ≥ 5% and ≥ 10% weight loss versus placebo (adjusted OR: 2.0, P = 0.0008; OR: 2.1, P = 0.0107, respectively), with 5% responders having a mean weight loss of 10.2%. Patients with prediabetes or drug-naive type 2 diabetes had six times the odds of achieving ≥ 10% weight loss. Gelesis100 treatment had no apparent increased safety risks.
conclusionsGelesis100 is a promising new nonsystemic therapy for overweight and obesity with a highly desirable safety and tolerability profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.